• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Life Sciences | News, Analysis, Insights - HIT Consultant

Novo Nordisk Amps Up Drug Discovery with Gefion AI Supercomputer

by Syed Hamza Sohail 06/11/2025 Leave a Comment

Novo Nordisk Amps Up Drug Discovery with Gefion AI Supercomputer

What You Should Know: -DCAI today announced that Novo Nordisk has become a customer of the Gefion AI supercomputer. - Through this agreement, Novo Nordisk will gain access to Gefion's unparalleled computational capabilities to process vast datasets, with a goal of transforming drug discovery and development as well as driving healthcare innovation.  AI-Powered Supercomputing Alliance to Advance Drug Discovery at Scale In a landmark multiyear agreement, Novo Nordisk and Gefion have
Read More

Lieber Institute and AWS Collaborate to Optimize Drug Discovery for Brain Disorders

by Fred Pennic 06/10/2025 Leave a Comment

Lieber Institute and AWS Collaborate to Optimize Drug Discovery for Brain Disorders

What You Should Know:  - The Lieber Institute for Brain Development (LIBD) is expanding its technology capabilities on Amazon Web Services (AWS), migrating its IT infrastructure to fully utilize AWS generative AI and compute services to advance its research.  - A recipient of the 2024 AWS IMAGINE Grant, the Institute plans to develop a new tool called GRAPE that combines generative and predictive AI to find new, more effective treatments for brain disorders such as
Read More

From Raw Records to Real-Time Insights: Climbing Pharma’s Real-World Data Maturity Curve

by Viraj Narayanan, CEO at Cornerstone AI & Daniel Lane, Head of RWD Strategy & Operations at Bristol Myers Squibb 06/10/2025 Leave a Comment

From Raw Records to Real-Time Insights: Climbing Pharma’s Real-World Data Maturity Curve

Real-world data (RWD) has become the pharmaceutical industry's most promising yet challenging frontier. While companies have long recognized its potential to complement clinical trials and deepen patient outcome insights, many still struggle to fully realize its value. We’ve seen firsthand, from early discovery to market authorization to post-launch evidence generation, that extracting meaningful value from RWD requires more than just data acquisition. It demands a consistent, scalable, and
Read More

Nicoya Lifesciences Acquires Applied Photophysics to Accelerate Drug Discovery

by Syed Hamza Sohail 06/10/2025 Leave a Comment

Nicoya Lifesciences Acquires Applied Photophysics to Accelerate Drug Discovery

What You Should Know: -  Nicoya Lifesciences, Inc., a leading provider of advanced biologics characterization tools for drug discovery and development, today announced its acquisition of Applied Photophysics, a UK-based provider of biophysical characterization instrumentation.  -  Applied Photophysics, bringing a 50-year history of delivering established analytical methods and reliable instrumentation, will now operate as part of Nicoya. Nicoya Expands Biopharmaceutical Analytics
Read More

Mission Bio Unveils Industry-First Single-Cell Genotype and Targeted Gene Expression Solution

by Syed Hamza Sohail 06/05/2025 Leave a Comment

Mission Bio Unveils Industry-First Single-Cell Genotype and Targeted Gene Expression Solution

What You Should Know: - Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Single-Cell Genotype and Targeted Gene Expression assay, expanding the capabilities of its Tapestri Platform to become the only commercial solution that delivers simultaneous genotype and targeted gene expression profiling from over 10,000 single cells. - The assay, which can be leveraged for Phase 2 or 3 trials to home in on patients most likely to
Read More

Oxford Cancer Biomarkers and Mira Precision Health Partner to Advance ToxNav® Cancer Test

by Jasmine Pennic 06/02/2025 Leave a Comment

Oxford Cancer Biomarkers and Mira Precision Health Partner to Advance ToxNav® Cancer Test

What You Should Know:  - Oxford Cancer Biomarkers Ltd (OCB), a leader in molecular precision cancer diagnostic tests, has today announced a new partnership with Mira Precision Health Inc. - This collaboration aims to advance OCB's proprietary ToxNav® test in the United States, a revolutionary precision oncology tool designed to identify patients at high risk of severe toxicity from common chemotherapy treatments. - Mira Precision Health, headquartered at the Mason 5155 BioHub in
Read More

The NP/PA Factor: Why Advanced Practice Providers Are Essential for Life Sciences in 2025

by Deb Nevins, Chief Marketing & Strategy Officer at POCN Group 05/30/2025 Leave a Comment

The NP/PA Factor: Why Advanced Practice Providers Are Essential for Life Sciences in 2025

For decades, life sciences companies have centered their marketing efforts on physicians, assuming they hold the greatest influence over prescribing and treatment decisions. However, the healthcare landscape has shifted dramatically. Nurse practitioners (NPs) and physician assistants/associates (PAs) are not just supporting players, they are primary prescribers shaping patient care across nearly every therapeutic area. This shift is finally being recognized across the industry. According to
Read More

Kyron.bio Secures $6.2M to Optimize Biologic Drug Development with Precision Glycan Engineering

by Fred Pennic 05/28/2025 Leave a Comment

Kyron.bio Secures $6.2M to Optimize Biologic Drug Development with Precision Glycan Engineering

What You Should Know:  - Biotechnology company kyron.bio announced the successful closing of a $6.2M (€5.5M) seed funding round aimed at solving critical challenges in biologic drug development, specifically varying efficacy and the dangers of side effects.  - The round was led by HCVC, with participation from Verve Ventures, Entrepreneurs First, Saras Capital, and numerous reputable angel investors. - The funds will be used to accelerate the development of kyron.bio’s proprietary
Read More

Brooklyn Health Secures $6.5M to Expand AI-Powered Precision for Clinical Trial Endpoints

by Fred Pennic 05/27/2025 Leave a Comment

Brooklyn Health Secures $6.5M to Expand AI-Powered Precision for Clinical Trial Endpoints

What You Should Know:  - Brooklyn Health, a neuroscience technology company focused on objective measurement of mental health announced it has secured $6.5M in seed funding led by HealthX, with participation from Metrodora Ventures, Story Ventures, RiverPark Ventures, Laconia Capital, Everywhere Ventures, Hypothesis Studio, Blue Falcon Capital, and others. - The funding coincides with the company's debut of its new electronic clinical outcome assessment (eCOA) solution, Willis. Willis
Read More

Key Features to Look for in a Microplate Luminometer

by HITC Staff 05/27/2025 Leave a Comment

Microplate luminometers play a critical role in luminescence-based assays, powering applications ranging from cell signaling studies to high-throughput drug screening. With a wide variety of models available on the market, selecting the right instrument means ensuring it includes the essential features that will deliver reliable, sensitive, and reproducible results. Below are the key features to prioritize when choosing a microplate luminometer: 1. Luminescence Sensitivity Sensitivity is
Read More

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 85
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |